Man Group 13F: Adds $26M to Alnylam Pharmaceuticals (ALNY) Stake

Man Group Raises Position in Alnylam

Man Group filed a Form 13F with the Securities and Exchange Commission showing a sizeable expansion of its investment in Alnylam Pharmaceuticals, Inc. (NasdaqGS: ALNY). The fund lifted its stake by 61.1% during the period, picking up 88,159 shares to bring its total ownership to 232,369 shares. Based on the reporting period values, that expanded stake carried an estimated market value of $69,269,200.32.

Stock Performance and Recent Trading Levels

Shares of Alnylam traded around $298.10 as the wider market observed the fund's portfolio adjustments. The biotechnology company moves within a 52-week range stretching from a low of $197.81 up to a high of $495.55. Its current valuation places the trailing P/E ratio at 42.5, while the forward P/E ratio sits at 19.6. Investors should keep in mind that 13F filings are backward-looking documents that capture holdings at the close of a specific quarter and may not reflect current positions.

Wall Street Analyst Updates

Analyst opinion on the company remains broad, with 26 professionals contributing to a consensus buy rating and a mean price target of $371.35. On October 14, 2026, Citigroup maintained its buy rating on the stock while adjusting its price target to $320.00 from $340.00. On the same day, Wells Fargo maintained an equal-weight rating with a price target of $253.00 down from $256.00. Earlier in October, RBC Capital maintained an outperform rating with a $345.00 target, while JP Morgan maintained an overweight rating and a $369.00 target on September 30, 2026. HC Wainwright & Co. reiterated a buy rating with a $455.00 target on September 21, 2026, and Jefferies maintained a hold rating with a $260.00 target on September 8, 2026.

Company Focus and Background

Alnylam Pharmaceuticals, Inc. discovers and develops RNA interference therapeutics aimed at treating rare and severe genetic conditions. Headquartered in Cambridge, Massachusetts, the firm employs roughly 2,500 people and commercializes several approved treatments while advancing a deep clinical pipeline across multiple therapeutic areas. This institutional portfolio shift by Man Group arrives as the biotechnology firm continues to advance its core drug portfolio.

Upcoming Financial Milestones

The company's next quarterly financial results are scheduled for release on October 29, 2026, which will offer fresh visibility into its ongoing commercial progress and pipeline developments. Market watchers will look to these upcoming disclosures alongside future institutional filing updates to track how large asset managers manage their exposure to the healthcare sector.